ArticleWorld journal of gastroenterology2018
Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts.BMC gastroenterology · 2026Pooled it
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.BMJ open · 2022Pooled it
- The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.Liver cancer · 2026Review
- Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD.JHEP reports : innovation in hepatology · 2026Article
- Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatment.Japanese journal of radiology · 2026Review
- Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD).Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- The importance of patient engagement in the multimodal treatment of MASLD.Communications medicine · 2025Review
- Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors.Digestive diseases and sciences · 2025Review
- Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy.Journal of viral hepatitis · 2025Article
- Hormone replacement therapy for steatotic liver management after surgical menopause.Clinical journal of gastroenterology · 2025Article
- MetALD: Clinical aspects, pathophysiology and treatment.JHEP reports : innovation in hepatology · 2025Review
- Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy.Scientific reports · 2024Article
- Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review.Ewha medical journal · 2024Review
- Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.Journal of the Canadian Association of Gastroenterology · 2024Review
- Hepatic changes following a high-fat diet: effects ofMedicine and pharmacy reports · 2024Article
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease.United European gastroenterology journal · 2024Review
- Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease.Nutrients · 2024Review
- Comparison of Clinical Manifestations and Related Factors of Hepatocellular Carcinoma with Chronic Hepatitis B.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe impact of mild drinking habit (less than 20 g/d of ethanol) on the clinical course of non-alcoholic fatty liver disease (NAFLD) has not been determined. We examined the influence of a mild drinking habit on liver carcinogenesis from NAFLD.
methodsA total of 301 patients who had been diagnosed as having NAFLD by liver biopsy between 2003 and 2016 [median age: 56 years, 45% male, 56% with non-alcoholic steatohepatitis, 26% with advanced fibrosis (F3-4)] were divided into the mild drinking group with ethanol consumption of less than 20 g/d (mild drinking group,
resultsWe observed significant differences in male prevalence (
conclusionA mild drinking habit appears to be a risk factor for hepatocarcinogenesis in NAFLD patients, especially those with advanced fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.